Quantcast

Latest linezolid Stories

2009-05-18 07:00:00

Data on frequency of resistance development and safety presented at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) SAN DIEGO, May 18 /PRNewswire/ -- Trius Therapeutics, Inc., a biopharmaceutical company developing best-in-class drugs for the treatment of serious bacterial infections, announced new data today from multiple studies of torezolid (TR-701), a novel antibiotic that is a potent inhibitor of gram-positive bacteria including methicillin-resistant...

2009-05-07 10:19:00

NEW HAVEN, Conn., May 7 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, today announced that researchers will be presenting two presentations and two posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) taking place in Helsinki, Finland from May 16-19, 2009. Independent researchers,...

2009-05-06 07:00:00

Clinical results and advantage over linezolid in resistance acquisition by Staph aureus among data to be presented at infectious disease meeting SAN DIEGO, Calif., May 6 /PRNewswire/ -- Trius Therapeutics, Inc., a biopharmaceutical company developing best-in-class drugs for the treatment of serious bacterial infections, announced today that the results of multiple studies from its lead program, torezolid (TR-701), will be presented in an oral session and six poster presentations at the 19th...

2009-04-20 07:00:00

Renowned Physicians Join World Class Group of Advisors SAN DIEGO, April 20 /PRNewswire/ -- Trius Therapeutics, Inc. today announced the expansion of its Clinical Advisory Board, naming Donald H. Batts, MD, FACP, FIDSA, and G. Ralph Corey, MD, as the sixth and seventh members of the group of anti-infective thought leaders. Dr. Batts is a Professor of Medicine at Michigan State University and the Chief of Infectious Diseases at its Kalamazoo Campus. Dr. Corey is the Gary Hock...

2009-04-15 07:00:00

NEW HAVEN, Conn., April 15 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, today announced the issuance of a key antibiotic patent in China. The State Intellectual Property Office of the People's Republic of China has issued Chinese Patent Number ZL 2004 8 0021883.9 to Rib-X. This patent provides composition of matter...

2009-04-13 11:30:21

Residents of nursing homes are one of the main reservoirs of anti-microbial resistant bacteria, U.S. researchers said. Study leader Dr. Erin' O'Fallon, a geriatrician at Hebrew Rehabilitation Center and a research fellow in medicine at Harvard Medical School in Boston said that the prevalence of a certain form of drug-resistant bacteria -- multidrug-resistant gram-negative organisms -- far surpassed that of two other common antimicrobial-resistant infections in long-term care facilities....

2009-02-12 09:52:00

PHILADELPHIA, Feb. 12 /PRNewswire-USNewswire/ -- When treating children for acute osteomyelitis--a bacterial bone infection--an early changeover from intravenous (IV) antibiotic delivery to oral antibiotics is just as effective as continuing the IV therapy, according to pediatric researchers. In addition, the oral drugs are more convenient for children and families, and avoid a major drawback of IV use: increased risk of complications from using central catheters, such as infections or...

2009-01-25 23:15:00

180 Patient Trial of 2nd Generation Oxazolidinone Enrolls in Four Months SAN DIEGO, Jan. 26 /PRNewswire/ -- Trius Therapeutics, Inc. today announced the completion of enrollment in its randomized, double-blind Phase 2 clinical trial testing the oral dosage form of torezolid (also known as TR-701) in patients with complicated skin and skin structure infections (cSSSI). The trial, which was conducted in 12 clinical sites in the United States, examined the efficacy and safety of three dosage...

2008-11-13 09:00:37

Australian biotechnology company Avexa (ASX:AVX) today announced the presentation of 48 week data from its apricitabine program at the Ninth International Congress on Drug Therapy in HIV Infection held in Glasgow, UK, 9-13 November 2008. The previous week the company presented data on its antibacterial program at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) / Infectious Diseases Society of America (IDSA) 46th annual meeting, held 25-28 October 2008, in...

2008-11-04 09:00:30

MALVERN, Pa. and WALTHAM, Mass., Nov. 4 /PRNewswire/ -- Arlington Medical Resources (AMR) and Decision Resources find that with the rising incidence of skin infections caused by methicillin-resistant Staphylococcus aureus (MRSA), an overwhelming majority of surveyed physicians indicate that the most important attribute influencing antibiotic selection in skin and skin structure infections (SSSIs) is activity against MRSA. Other factors that influence drug selection include an agent's skin...


Latest linezolid Reference Libraries

0_4d46cc72a490344d44ba78359f528175
2011-04-26 21:07:20

Enterococcus is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is a main constituent of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans, especially in the nosocomial environment, where the naturally high levels of antibiotic resistance found in E. faecalis contribute to its pathogenicity. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of...

0_71ad70ea6f0948a7e84406e760c7f5a4
2011-04-15 14:36:05

Enterococcus faecalis "“ formerly classified as part of the Group D Streptococcus system "“ is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is one of the main constituents of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of the cases. It is a non-motile, facultatively anaerobic...

More Articles (2 articles) »
Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related